BEnefit of Arterial Preparation by LONGitudinal Scoring (BELONG)
BEnefit of Arterial Preparation by LONGitudinal Scoring Before Paclitaxel Eluting Balloon Angioplasty of the Superficial Femoral and Popliteal Artery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jill Schweiger
- Phone Number: 763-296-2021
- Email: jschweiger@venturemedgroup.com
Study Locations
-
-
-
Fribourg, Switzerland
- Hôpital Cantonal de Fribourg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ≥ 18-year-old, with symptomatic lower extremity occlusive arterial disease
- Rutherford class of symptom 2 to 5
- Atheromatous ≥ 70 % stenosis or occlusion of SFA and/or PA
- Absence of > 50% residual stenosis of the run-in vessels at the end of procedure
- Presence of at least one patent (no ≥ 50 % stenosis) run-off tibial or fibular vessel to the foot at the end of procedure
- De novo or restenotic lesions, including in-stent restenosis
- Willingness to participate in the study and signature of informed consent
Exclusion Criteria:
- Renal failure with glomerular filtration rate (GFR) 30 ml/min or below, estimated by the Cockroft-Gault equation.
- Women who are pregnant, lactating, or planning to become pregnant during the duration of the study
- Recent artery thrombosis, at risk of distal embolization during percutaneous procedure
- Previous use of a PCB in the lesion during last 15 months
- Extremely calcified lesions, defined by calcification involving ³ 270° of the artery circumference over ³ 15 cm.
- Sub-intimal recanalization
- Tortuous contra-lateral femoral access with difficult cross-over
- Previous or planned surgery of the target lesion
- High risk of bleeding
- Contra-indication to dual antiplatelet therapy for one month, and/or to single antiplatelet therapy for 1 year
- Allergy to aspirin, clopidogrel or heparin
- Life expectancy less than one year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FLEX Scoring Catheter plus DEB
The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage.
Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
|
Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absence of clinically driven target lesion revascularization (CDTLR) at 12 months
Time Frame: 12 months
|
12 months
|
|
Occurrence of death from cardiovascular origin
Time Frame: 12 months
|
12 months
|
|
Occurrence of major amputation of target limb
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary patency of the treated lesion (defined by PSVR ≤ 2.5 at duplex scan)
Time Frame: 3 and 12 months
|
3 and 12 months
|
|
Absence of CDTLR
Time Frame: 3 months
|
3 months
|
|
Absence of major amputation
Time Frame: 3 and 12 months
|
3 and 12 months
|
|
Change in ankle brachial index (ABI)
Time Frame: 3 and 12 months
|
3 and 12 months
|
|
Change in Rutherford class of symptom
Time Frame: 3 and 12 Months
|
3 and 12 Months
|
|
Technical success of the scoring procedure
Time Frame: Average of 2 hours
|
Average of 2 hours
|
|
Proportion of luminal gain
Time Frame: Average of 2 hours
|
Average of 2 hours
|
|
Occurrence of dissection
Time Frame: Average of 2 hours
|
Average of 2 hours
|
|
Proportion of stent implantation
Time Frame: Average of 2 hours
|
Average of 2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Daniel Periard, MD, Fribourg Cantonal Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BELONG Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.